Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015 Oct 15; 75(20):4384-4397.
View in:
PubMed
subject areas
3' Untranslated Regions
Animals
Apoptosis Regulatory Proteins
bcl-2 Homologous Antagonist-Killer Protein
bcl-2-Associated X Protein
Binding Sites
Cell Line, Tumor
Dexamethasone
Disease Models, Animal
Drug Resistance, Neoplasm
Gene Expression Regulation, Neoplastic
Humans
Mice
MicroRNAs
Multiple Myeloma
Neoplasm Metastasis
Proto-Oncogene Proteins
RNA Interference
Signal Transduction
Tumor Burden
Xenograft Model Antitumor Assays
authors with profiles
Kenneth Carl Anderson, M.D.
Nikhil C Munshi, M.D., M.B.,B.S.
Yu-Tzu Tai, Ph.D.
Ruben D. Carrasco, Ph.D., M.D.